NCT04469920View on ClinicalTrials.gov

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

Saroglitazar Magnesium 2 mg

1 tablet, single dose at Day 1

DRUG

Saroglitazar Magnesium 4 mg

1 tablet, single dose at Day 1

Trial Locations (2)

46202

Indiana University School of Medicine, Indianapolis

78215

American Research Corporation at Texas Liver Institute, San Antonio

All Listed Sponsors

lead

Zydus Therapeutics Inc.

INDUSTRY

NCT04469920 - Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function | Biotech Hunter | Biotech Hunter